Literature DB >> 22120098

Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan.

Masayuki Furukawa1, Ken Umehara, Eiji Kashiyama.   

Abstract

PURPOSE: To evaluate the pharmacokinetic profile of tolvaptan.
METHOD: The nonclinical pharmacokinetic profile of [(14)C]tolvaptan was evaluated in an absorption, distribution, and excretion study in rats after single oral administration. An in vitro protein binding study was also performed.
RESULTS: The tolvaptan-derived radioactivity was rapidly absorbed and extensively distributed to all tissues in rats. The radioactivity levels were greatest in the gastrointestinal tract and liver, though the levels in the cerebrum, cerebellum and medulla oblongata were low. The serum and tissue concentrations of radioactivity, and serum concentration of tolvaptan in male and female rats showed a marked sex difference. The radioactivity was crossed the placenta and was distributed to the fetal tissues in pregnant rats. The milk showed 1.5-15.8-fold higher radioactivity than blood in lactating rats. The radioactivity mainly excreted into the feces via the biliary route. Tolvaptan binds extensively to plasma proteins (≥ 97.2%) in mouse, rat, rabbit, dog and human plasma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22120098     DOI: 10.1007/s10557-011-6357-x

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  8 in total

1.  Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes.

Authors:  Yang Lu; Jason R Slizgi; Kenneth R Brouwer; Robert L St Claire; Kimberly M Freeman; Maxwell Pan; William J Brock; Kim L Brouwer
Journal:  Drug Metab Dispos       Date:  2016-03-24       Impact factor: 3.922

2.  miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model.

Authors:  Merrie Mosedale; J Scott Eaddy; O Joseph Trask; Natalie S Holman; Kristina K Wolf; Edward LeCluyse; Brenton R Ware; Salman R Khetani; Jingtao Lu; William J Brock; Sharin E Roth; Paul B Watkins
Journal:  Toxicol Sci       Date:  2018-01-01       Impact factor: 4.849

3.  Elamipretide treatment during pregnancy ameliorates the progression of polycystic kidney disease in maternal and neonatal mice with PKD1 mutations.

Authors:  Nastaran Daneshgar; Peir-In Liang; Renny S Lan; McKenna M Horstmann; Lindsay Pack; Gourav Bhardwaj; Christie M Penniman; Brian T O'Neill; Dao-Fu Dai
Journal:  Kidney Int       Date:  2021-12-22       Impact factor: 18.998

4.  Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan.

Authors:  Isao Sakaida; Koji Nakajima; Kiwamu Okita; Masatsugu Hori; Tohru Izumi; Masaya Sakurai; Yoshiyuki Shibasaki; Sayaka Tachikawa; Hidetsugu Tsubouchi; Hiromi Oka; Hiroyuki Kobayashi
Journal:  J Gastroenterol       Date:  2015-02-18       Impact factor: 7.527

5.  Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria.

Authors:  Koji Takagi; Naoki Sato; Shiro Ishihara; Michiko Sone; Hideo Tokuyama; Kenji Nakama; Toshiya Omote; Arifumi Kikuchi; Masahiro Ishikawa; Kenichi Amitani; Naoto Takahashi; Yuji Maruyama; Hajime Imura; Wataru Shimizu
Journal:  Heart Vessels       Date:  2017-10-23       Impact factor: 2.037

6.  Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity.

Authors:  James J Beaudoin; William J Brock; Paul B Watkins; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2020-09-08       Impact factor: 6.875

7.  Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.

Authors:  Jeffrey L Woodhead; William J Brock; Sharin E Roth; Susan E Shoaf; Kim L R Brouwer; Rachel Church; Tom N Grammatopoulos; Linsey Stiles; Scott Q Siler; Brett A Howell; Merrie Mosedale; Paul B Watkins; Lisl K M Shoda
Journal:  Toxicol Sci       Date:  2016-09-21       Impact factor: 4.849

Review 8.  Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) During Pregnancy: Risks and Challenges.

Authors:  Lucy McBride; Catherine Wilkinson; Shilpanjali Jesudason
Journal:  Int J Womens Health       Date:  2020-05-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.